Journal of Adolescent Health
Volume 46, Issue 2 , Pages 142-151 , February 2010

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis–inactivated Poliovirus Vaccine to Girls and Young Women

  • José Garcia-Sicilia, M.D.

      Affiliations

    • Hospital Infantil Universitario La Paz, Madrid, Spain
    • Corresponding Author InformationAddress correspondence to: José Garcia-Sicilia, M.D., Hospital Infantil Universitario La Paz, Madrid, Spain.
    • ,
  • Tino F. Schwarz, M.D.

      Affiliations

    • Stiftung Juliusspital Wuerzburg, Wuerzburg, Germany
    • ,
  • Alfonso Carmona, M.D.

      Affiliations

    • Instituto Hispalense de Pediatría, Sevilla, Spain
    • ,
  • Klaus Peters, M.D.

      Affiliations

    • Praxis, Hamburg, Germany
    • ,
  • Jean-Elie Malkin, M.D.

      Affiliations

    • Centre Médical de l'Institut Pasteur, Paris, France
    • ,
  • Phu M. Tran, M.D.

      Affiliations

    • Cabinet Médical, Nice, France
    • ,
  • Ulrich Behre, M.D.

      Affiliations

    • Medical Practice Kehl, Kehl, Germany
    • ,
  • Enrique B. Iturbe, M.D.

      Affiliations

    • Hospital Virgen del Camino, Pamplona, Spain
    • ,
  • Gregory Catteau, M.Sc.

      Affiliations

    • GlaxoSmithKline Biologicals, Rixensart, Belgium
    • ,
  • Florence Thomas, M.D., D.T.M.

      Affiliations

    • GlaxoSmithKline Biologicals, Rixensart, Belgium
    • ,
  • Kurt Dobbelaere, M.D.

      Affiliations

    • GlaxoSmithKline Biologicals, Rixensart, Belgium
    • ,
  • Dominique Descamps, M.D.

      Affiliations

    • GlaxoSmithKline Biologicals, Rixensart, Belgium
    • ,
  • Gary Dubin, M.D.

      Affiliations

    • GlaxoSmithKline Biologicals, King of Prussia, Pennsylvania
    • ,
  • HPV Vaccine Adolescent Study Investigators Network

Received 24 July 2009 ,Accepted 18 November 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: A review. Bull World Health Organ. 2007;85:719–726
  3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19
  4. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–265
  5. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907
  6. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182–192
  7. Moscicki AB. HPV infections in adolescents. Dis Markers. 2007;23:229–234
  8. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed). [ Cervarix™] Drugs. 2008;68:359–372
  9. Stanley M. Prophylactic HPV vaccines: Prospects for eliminating ano-genital cancer. Br J Cancer. 2007;96:1320–1323
  10. Barr E, Sings HL. Prophylactic HPV vaccines: New interventions for cancer control. Vaccine. 2008;26:6244–6257
  11. Koulova A, Tsui J, Irwin K, et al. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008. Vaccine. 2008;26:6529–6541
  12. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries–key challenges and issues. N Engl J Med. 2007;356:1908–1910
  13. Frampton JE, Keating GM. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix™): A review of its use as a single-dose booster immunization. BioDrugs. 2006;20:371–389
  14. Vergara R, Tregnaghi M, Ussher J, et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr. 2005;164:377–382
  15. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5:332–340
  16. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 2004;364:1757–1765
  17. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet. 2006;367:1247–1255
  18. Harper D, Gall S, Naud P, et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow up through 6.4 years in women vaccinated with Cervarix™ (GSK's HPV 16/18 AS04 candidate vaccine) [abstract]. Paper Presented at: Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancer; March 9–12, 2008; Tampa, FL.
  19. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–2170
  20. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–314
  21. Dagan R, Igbaria K, Piglansky L, et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatr Infect Dis J. 1997;16:1113–1121
  22. Gylca R, Gylca V, Benes O, et al. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10, and 14 weeks following HBV at birth. Vaccine. 2000;19:825–833
  23. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin. 2008;4:425–434
  24. Theeten H, Rumke H, Hoppener FJ, et al. Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Curr Med Res Opin. 2007;23:2729–2739
  25. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1–34
  26. Wheeler CM, Bautistac OM, Tomassinic JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine. 2008;26:686–696
  27. Pedersen C, Petaja T, Strauss G, et al. Immunization of adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564–571

 Conflict of interest: Gregory Catteau, Dominique Descamps, Kurt Dobbelaere, Gary Dubin, and Florence Thomas are employees of GlaxoSmithKline Biologicals; Jose Garcia-Sicilia has participated, as a principal investigator, in clinical trials on vaccines, funded by GlaxoSmithKline; Alfonso Carmona has participated, as an investigator, in several clinical trials funded by GlaxoSmithKline; Enrique Bernaola Iturbe is on the Speaker's Bureau for GlaxoSmithKline, Sanofi Pasteur, MSD and Wyeth and is also an advisory board member for AstraZeneca; Tino F. Schwarz, Klaus Peters, Jean-Elie Malkin, and Phu M. Tran have no conflict of interest with regard to this study.

PII: S1054-139X(09)00629-6

doi: 10.1016/j.jadohealth.2009.11.205

Journal of Adolescent Health
Volume 46, Issue 2 , Pages 142-151 , February 2010

Article Tools

* Image Usage & Resolution